Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2012 Aug 30;39(5):577–590. doi: 10.1007/s10928-012-9269-x

Table 4.

Dulanermin dosing regimens for tumor xenograft studies with average data

Treatment group ID Dose (mg/kg/dose) Dose regimen Number of data sets
Dlmn23 (a, b, c) Control No drug 3 sets of average data
Dlmn24 25 IP bolus for two cycles of 5 consecutive days, with 16 days of rest between cycles 1 set of average data
Dlmn25 25 IP bolus three times per week for 5 weeks 1 set of average data
Dlmn26 25 IP bolus for two cycles of 14 consecutive days, with 7 days of rest between cycles 1 set of average data
Dlmn27 30 IV bolus for two cycles of a dose given every 24 h for 5 consecutive doses with 3 days of rest between cycles 1 set of average data
Dlmn28 30 IV bolus for two cycles of a dose given every 12 h for 5 consecutive doses with 5 1/2 days of rest between cycles 1 set of average data
Dlmn29 30 IV bolus for two 2 cycles of a dose given every 2 h for 5 consecutive doses with 7 2/3 days of rest between cycles 1 set of average data
Dlmn30 60 IV bolus on day 0 1 set of average data
Dlmn31 60 IV bolus on days 0 and 3 1 set of average data
Dlmn32 60 IV bolus for 5 consecutive days (days 0, 1, 2, 3, 4) 1 set of average data
Dlmn33 90 IV bolus on day 0 1 set of average data

The letters a, b, c, etc. are defined above